Depomed Company Profile (NASDAQ:DEPO)

About Depomed

Depomed logoDepomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Company's products include NUCYNTA ER (tapentadol extended release tablets), which is a product for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate; NUCYNTA (tapentadol), which is an immediate release version of tapentadol for the management of moderate to severe acute pain in adults; Gralise, which is a once-daily product for the management of postherpetic neuralgia; CAMBIA, which is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Zipsor, which is a NSAID for the treatment of mild to moderate acute pain, and Lazanda nasal spray, which is used for the management of break through pain in cancer patients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: DEPO
  • CUSIP: 24990810
Key Metrics:
  • Previous Close: $19.77
  • 50 Day Moving Average: $19.92
  • 200 Day Moving Average: $17.89
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 13.27
  • P/E Growth: 0.90
  • Market Cap: $1.21B
  • Outstanding Shares: 61,366,000
  • Beta: 1.16
Additional Links:
Companies Related to Depomed:

Analyst Ratings

Consensus Ratings for Depomed (NASDAQ:DEPO) (?)
Ratings Breakdown: 3 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.73)
Consensus Price Target: $23.18 (17.26% upside)

Analysts' Ratings History for Depomed (NASDAQ:DEPO)
DateFirmActionRatingPrice TargetDetails
8/11/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details
8/4/2016Piper Jaffray Cos.Reiterated RatingNeutral$18.00 -> $19.00View Rating Details
8/4/2016JMP SecuritiesLower Price TargetMarket Outperform$28.00 -> $22.00View Rating Details
8/4/2016Janney Montgomery ScottReiterated RatingBuy$28.00View Rating Details
8/4/2016MizuhoReiterated RatingBuy$23.00View Rating Details
7/18/2016Leerink SwannReiterated RatingPositiveView Rating Details
7/11/2016Royal Bank Of CanadaReiterated RatingHoldView Rating Details
3/28/2016Roth CapitalReiterated RatingBuyView Rating Details
3/24/2016Northland SecuritiesInitiated CoverageOutperform$22.00View Rating Details
2/24/2016WallachBeth CapitalLower Price TargetBuy$33.00 -> $27.00View Rating Details
12/3/2015Morgan StanleyInitiated CoverageEqual -> Equal Weight$21.00View Rating Details
(Data available from 8/25/2014 forward)


Earnings History for Depomed (NASDAQ:DEPO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2016Q2$0.26$0.27$118.20 million$116.70 millionViewListenView Earnings Details
5/5/2016Q1$0.17$0.12$106.88 million$104.60 millionViewListenView Earnings Details
2/22/2016Q415$0.29$0.16$110.19 million$111.20 millionViewListenView Earnings Details
11/9/2015Q3$0.19$0.33$101.64 million$105.00 millionViewListenView Earnings Details
7/29/2015Q215($0.45)$0.27$88.33 million$94.30 millionViewListenView Earnings Details
5/11/2015Q115$0.07($0.13)$33.80 million$31.70 millionViewListenView Earnings Details
2/23/2015Q414$0.07$0.21$44.66 million$33.90 millionViewListenView Earnings Details
11/5/2014Q314($0.04)$0.03$41.50 million$51.49 millionViewListenView Earnings Details
8/6/2014Q214($0.08)($0.01)$38.03 million$67.70 millionViewListenView Earnings Details
5/8/2014Q114$0.10($0.01)$53.57 million$76.50 millionViewListenView Earnings Details
3/12/2014Q413($0.21)$0.72$19.06 million$40.60 millionViewListenView Earnings Details
11/5/2013Q313$0.07$0.11$35.55 million$37.50 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.05)$0.01$29.87 million$30.00 millionViewListenView Earnings Details
5/8/2013Q1 2013($0.06)($0.10)$28.93 million$26.20 millionViewListenView Earnings Details
2/20/2013Q4 2012($0.11)($0.07)$26.48 million$26.60 millionViewListenView Earnings Details
11/5/2012Q312($0.11)($0.03)$28.06 million$33.30 millionViewN/AView Earnings Details
8/2/2012($0.22)($0.28)ViewN/AView Earnings Details
5/8/2012($0.24)($0.16)ViewN/AView Earnings Details
3/8/2012($0.31)($0.25)ViewN/AView Earnings Details
11/1/2011($0.23)($0.15)ViewN/AView Earnings Details
8/1/2011($0.05)($0.11)ViewN/AView Earnings Details
5/5/2011$1.05$1.77ViewN/AView Earnings Details
3/3/2011$0.06$0.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Depomed (NASDAQ:DEPO)
Current Year EPS Consensus Estimate: $1.21 EPS
Next Year EPS Consensus Estimate: $1.49 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.22)($0.22)($0.22)
Q2 20161($0.14)($0.14)($0.14)
Q3 20161$0.04$0.04$0.04
Q4 20161$0.09$0.09$0.09
Q1 20171$0.04$0.04$0.04
Q2 20171$0.07$0.07$0.07
Q3 20171$0.11$0.11$0.11
Q4 20171$0.22$0.22$0.22
(Data provided by Zacks Investment Research)


Dividend History for Depomed (NASDAQ:DEPO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Depomed (NASDAQ:DEPO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/10/2016August J. MorettiCFOSell5,000$21.40$107,000.00View SEC Filing  
8/10/2016Thadd M VargasVPSell26,290$20.92$549,986.80View SEC Filing  
5/23/2016Thadd M VargasVPSell15,000$20.00$300,000.00View SEC Filing  
5/10/2016Thadd M VargasVPSell15,000$17.64$264,600.00View SEC Filing  
5/9/2016August J MorettiCFOSell5,000$18.00$90,000.00View SEC Filing  
3/11/2016Thadd M VargasVPSell23,000$16.00$368,000.00View SEC Filing  
12/3/2015August J. MorettiCFOSell15,000$18.11$271,650.00View SEC Filing  
6/12/2015Thadd M VargasVPSell5,000$20.70$103,500.00View SEC Filing  
12/2/2014August J MorettiCFOSell5,339$15.85$84,623.15View SEC Filing  
12/2/2014James A SchoeneckCEOSell36,727$15.85$582,122.95View SEC Filing  
12/2/2014Thadd M VargasVPSell8,247$15.85$130,714.95View SEC Filing  
11/19/2014Matthew M GoslingVPSell71,000$15.36$1,090,560.00View SEC Filing  
3/14/2014James SchoeneckCEOSell17,000$14.54$247,180.00View SEC Filing  
3/14/2014Matthew GoslingVPSell21,875$14.74$322,437.50View SEC Filing  
12/2/2013Michael Md SweeneyCMOSell4,270$8.40$35,868.00View SEC Filing  
12/2/2013Thadd VargasVPSell5,296$8.40$44,486.40View SEC Filing  
5/10/2013James A SchoeneckCEOBuy25,000$5.11$127,750.00View SEC Filing  
3/6/2013Karen A DawesDirectorBuy2,000$5.96$11,920.00View SEC Filing  
8/14/2012Peter D StapleDirectorBuy5,000$5.01$25,050.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Depomed (NASDAQ:DEPO)
DateHeadline logoShort Interest Declines 12.4% For DEPO (NASDAQ:DEPO) - August 25 at 4:38 PM
News IconDrug Makers' Stocks Under Scanner: Amarin, Depomed, United Therapeutics, & Sucampo Pharma (NASDAQ:DEPO) - August 17 at 8:29 AM logoWhy a N.Y. hedge fund wants this drug company to run like Olive Garden (NASDAQ:DEPO) - August 17 at 8:29 AM logoDrug Makers Stocks Under Scanner -- Amarin, Depomed, United Therapeutics, and Sucampo Pharma (NASDAQ:DEPO) - August 16 at 4:41 PM logoDepomed, Inc. :DEPO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:DEPO) - August 12 at 4:38 PM logoDEPOMED INC Financials (NASDAQ:DEPO) - August 11 at 4:43 PM logo[$$] Drugmakers hooked on $10bn opioid habit (NASDAQ:DEPO) - August 10 at 8:21 AM logoDepomed: Focus On Nucynta Litigation Outcome - Seeking Alpha (NASDAQ:DEPO) - August 9 at 5:39 PM logoDepomed, Inc. (NASDAQ:DEPO) Earns Consensus Hold Rating - Review Fortune (NASDAQ:DEPO) - August 9 at 8:58 AM logoETF’s with exposure to Depomed, Inc. : August 8, 2016 (NASDAQ:DEPO) - August 8 at 4:42 PM logoAttention Grabbing Analyst Research Reports: Matador Resources Co (NYSE:MTDR), Depomed Inc (NASDAQ:DEPO) - Review Fortune (NASDAQ:DEPO) - August 5 at 4:39 PM logoKeep an eye on Analyst Actions: Depomed, Inc. (NASDAQ:DEPO) , Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Street Updates (NASDAQ:DEPO) - August 5 at 4:39 PM logoDepomed, Inc. breached its 50 day moving average in a Bullish Manner : DEPO-US : August 5, 2016 (NASDAQ:DEPO) - August 5 at 9:24 AM logoAnalyst Bullish Towards Depomed Inc (DEPO) (NASDAQ:DEPO) - August 4 at 4:50 PM logoEdited Transcript of DEPO earnings conference call or presentation 3-Aug-16 8:30pm GMT (NASDAQ:DEPO) - August 4 at 9:21 AM logoBRIEF-Depomed reports second quarter 2016 financial results (NASDAQ:DEPO) - August 3 at 10:13 PM logoDepomed Inc Earnings Call (Q2 2016) (NASDAQ:DEPO) - August 3 at 10:13 PM logoDepoMed Inc.: Depomed Reports Second Quarter 2016 Financial Results (NASDAQ:DEPO) - August 3 at 10:13 PM logo10-Q: DEPOMED INC (NASDAQ:DEPO) - August 3 at 10:13 PM logoDepomed reports 2Q loss (NASDAQ:DEPO) - August 3 at 10:13 PM logoEarnings Reaction History: Depomed, Inc., 85.7% Follow-Through Indicator, 6.2% Sensitive - Nasdaq (NASDAQ:DEPO) - August 3 at 4:42 PM logoDEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:DEPO) - August 3 at 4:42 PM logoDepomed Reports Second Quarter 2016 Financial Results (NASDAQ:DEPO) - August 3 at 4:42 PM logoDepomed Inc Earnings Call scheduled for 4:30 pm ET today (NASDAQ:DEPO) - August 3 at 4:42 PM logoPiperJaffray Downgrades Depomed Inc to Neutral – Trade Calls - Trade Calls (NASDAQ:DEPO) - August 3 at 8:52 AM logoQ2 2016 Depomed Inc Earnings Release - After Market Close (NASDAQ:DEPO) - August 3 at 8:52 AM logoGlobal Pain Management Therapeutics Market - Patent Expiries of Blockbuster Drugs to Intensify Challenges … (NASDAQ:DEPO) - August 2 at 4:44 PM logoDepomed, Inc. (NASDAQ:DEPO) Analyst Rating in Focus - Investor Newswire (NASDAQ:DEPO) - August 2 at 9:23 AM logoAnalyst's Focused Stocks: Amgen Inc. (NASDAQ:AMGN) , Depomed, Inc. (NASDAQ:DEPO) - Street Updates (NASDAQ:DEPO) - August 2 at 9:23 AM logoDepomed Inc (DEPO): Starboard Value Blasts The Company’s Board, Hires Special Advisors (NASDAQ:DEPO) - July 28 at 9:00 PM logoPiper Jaffray Analyst Downgrades Depomed Inc (DEPO) - Smarter Analyst (NASDAQ:DEPO) - July 28 at 10:17 AM logoStarboard Value Letter To Depomed - Seeking Alpha (NASDAQ:DEPO) - July 28 at 10:17 AM logoDepomed to Report Second Quarter Fiscal Year 2016 Financial Results on Wednesday, August 3, 2016 (NASDAQ:DEPO) - July 27 at 4:28 PM
News IconHC Stocks Watchful: Depomed Inc (NASDAQ:DEPO), Celgene Corporation (NASDAQ:CELG) - share market updates (press release) (NASDAQ:DEPO) - July 26 at 10:40 PM logoStarboard Sends Letter to Depomed (DEPO); Will Aim to Control Timing of Special Meeting (NASDAQ:DEPO) - July 26 at 12:52 PM logoDepomed, Inc. (NASDAQ:DEPO) Expected To Post Sales Of $924 - Investor Newswire (NASDAQ:DEPO) - July 23 at 4:30 PM
News IconNoninvasive VNS Promising in Chronic Migraine Prevention (NASDAQ:DEPO) - July 22 at 4:31 PM
News IconStock Moving Lower for the Month; Investor Update on Depomed, Inc. (NASDAQ:DEPO) - Engelwood Daily (NASDAQ:DEPO) - July 21 at 8:03 AM logoDepomed Inc versus The Medicines Company Head to Head Compare - CML News (NASDAQ:DEPO) - July 19 at 9:53 PM
News IconDepomed, Inc. (NASDAQ:DEPO) Wall Street Analyst Recommendation Outlook - TGP (NASDAQ:DEPO) - July 19 at 4:40 PM logoANI Pharmaceuticals Inc versus Depomed Inc Head to Head Compare - CML News (NASDAQ:DEPO) - July 19 at 4:40 PM
News IconMedtronic PLC (NYSE:MDT) & Depomed Inc (NASDAQ:DEPO) are Hot Stocks - Money News (press release) (NASDAQ:DEPO) - July 19 at 4:40 PM logoDepomed : Announces Patent Trial and Appeal Board Denial of Inter Partes Review of NUCYNTA Patent (NASDAQ:DEPO) - July 19 at 4:40 PM logoAnalyst Rating Fluctuations to Observe: Depomed, Inc. (NASDAQ:DEPO) , Keryx Biopharmaceuticals, Inc. (NASDAQ ... - Street Updates (NASDAQ:DEPO) - July 19 at 4:40 PM logoBRIEF-Depomed says Patent Board Denies IPR of NUCYNTA Patent (NASDAQ:DEPO) - July 18 at 2:24 PM logo1:35 pm DepoMed announces the PTAB declined to institute the Inter Partes Review petition filed by Rosellini Scientific with respect to U.S. Patent No. 7,994,364 with respect to all patent claims subject of the petition (NASDAQ:DEPO) - July 18 at 1:35 PM logoDepomed Announces Patent Trial and Appeal Board Denial of Inter Partes Review of NUCYNTA Patent (NASDAQ:DEPO) - July 18 at 1:34 PM logoDepomed, Inc. (NASDAQ:DEPO) Yearly Sales Target At $997.235 - Investor Newswire (NASDAQ:DEPO) - July 16 at 8:00 AM
News IconWere Analysts Bullish Depomed Inc (NASDAQ:DEPO) This Week? - Consumer Eagle (NASDAQ:DEPO) - July 15 at 3:36 PM logoDepomed Inc versus Horizon Pharma plc Head to Head Compare - CML News (NASDAQ:DEPO) - July 14 at 4:51 PM


Depomed (NASDAQ:DEPO) Chart for Thursday, August, 25, 2016

Last Updated on 8/25/2016 by Staff